PDE5A and benign prostatic hyperplasia: In addition, the survey included 470 patients (57.2% of male patients) with BPH, 516 patients (28.6%) with cardiovascular disease, 390 patients (21.3%) taking α1 blockers, 112 patients (6.1%) taking anticholinergic agents, and 67 patients (3.7%) taking PDE5 inhibitors, for whom information was limited in clinical trials [16].